CDEK
← All organizations

Advanced Accelerator Applications

For profitContributed to NMEWebsite ↗

Also known as: Advanced Accelerator Applications | Advanced Accelerator Applications SA

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Feb 1, 2011

First marketed drug

Jun 1, 2016

First NDA

Jun 1, 2016

Last known activity

Oct 30, 2025

Acquired by Novartis on Jan 22, 2018

Timeline

2000s

  1. Jul 1, 2002

    Advanced Accelerator Applications— Founded

2010s

  1. Jan 1, 2015

    Atreus Pharmaceuticals CorporationAtreus Pharmaceuticals Corporation— Acquired

  2. Jan 22, 2018

    Novartis— Acquired By

  3. Jan 26, 2018

    lutetium dotatate lu-177— NDA Organization

Drugs by trial phase (23 distinct, 32 trials)

Phase 4 (2 own, 0 via acquisition)

Phase 1 (2 own, 1 via acquisition)

Other trials (1 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (2)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Recent trials (38)

Details

Founded
Saint Denis Pouilly, FR Jul 1, 2002
First NDA
Jun 1, 2016
Last known activity
Oct 30, 2025

Designations held

  • Orphan drug
  • Fast track
  • Priority review

Notes

Purchased by Novartis in October 2017